trending Market Intelligence /marketintelligence/en/news-insights/trending/xux4h5wr76zjxzztqdxnua2 content esgSubNav
In This List

Innate Immunotherapeutics changes name to Amplia Therapeutics

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Innate Immunotherapeutics changes name to Amplia Therapeutics

Innate Immunotherapeutics Ltd. is changing its name to Amplia Therapeutics Ltd.

The Australian pharmaceutical company will also change its stock code to ATX from IIL. Shareholders approved the changes at their annual general meeting in August.

The company said the changes are part of a wider branding refresh, as it focuses on therapeutic targets called focal adhesion kinase inhibitors. These can sensitize certain tumors to cancer drugs and chemotherapies.

Recently, the company found itself at the center of a U.S. congressman's insider trading scandal.